{"id":156834,"date":"2023-11-29T06:51:02","date_gmt":"2023-11-29T11:51:02","guid":{"rendered":"https:\/\/44.250.171.167\/?p=156834"},"modified":"2023-11-29T06:51:03","modified_gmt":"2023-11-29T11:51:03","slug":"gufic-biosciences-ltd-q2fy24-15-rise-in-profits","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/gufic-biosciences-ltd-q2fy24-15-rise-in-profits\/","title":{"rendered":"Gufic BioSciences Ltd Q2FY24; 15% rise in Profits"},"content":{"rendered":"<p>Gufic Biosciences Limited is engaged in the manufacture of pharmaceuticals, medicinal chemicals and botanical products.<\/p>\n<p>Financial Results:<\/p>\n<ul>\n<li>Gufic BioSciences Ltd reported Revenues for Q2FY24 of \u20b9215.00 Crores up from \u20b9175.00 Crore year on year, a rise of 22.86%.<\/li>\n<li>Total Expenses for Q2FY24 of \u20b9184.00 Crores up from \u20b9149.00 Crores year on year, a rise of 23.49%.<\/li>\n<li>Consolidated Net Profit of \u20b923.00 Crores up 15.0% from \u20b920.00 Crores in the same quarter of the previous year.<\/li>\n<li>The Earnings per Share is \u20b92.39, up 14.90% from \u20b92.08 in the same quarter of the previous year.<\/li>\n<\/ul>\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"839\" height=\"1024\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-375-839x1024.png\" alt=\"\" class=\"wp-image-156835\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-375-839x1024.png 839w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-375-246x300.png 246w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-375-768x937.png 768w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-375-1259x1536.png 1259w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-375.png 1489w\" sizes=\"auto, (max-width: 839px) 100vw, 839px\" \/><\/figure>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gufic Biosciences Limited is engaged in the manufacture of pharmaceuticals, medicinal chemicals and botanical products. Financial Results: Gufic BioSciences Ltd reported Revenues for Q2FY24 of \u20b9215.00 Crores up from \u20b9175.00 Crore year on year, a rise of 22.86%. Total Expenses for Q2FY24 of \u20b9184.00 Crores up from \u20b9149.00 Crores year on year, a rise of [&hellip;]<\/p>\n","protected":false},"author":1917,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,392],"tags":[12690],"class_list":["post-156834","post","type-post","status-publish","format-standard","hentry","category-infographics","category-earnings","tag-bioscience"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":153038,"url":"https:\/\/alphastreet.com\/india\/gufic-biosciences-ltd-q1fy24-18-rise-in-revenue\/","url_meta":{"origin":156834,"position":0},"title":"Gufic BioSciences Ltd Q1FY24; 18% rise in Revenue","author":"Hardik Bhandare","date":"August 11, 2023","format":false,"excerpt":"Gufic Biosciences Limited is engaged in the manufacture of pharmaceuticals, medicinal chemicals and botanical products. Financial Results: Gufic BioSciences Ltd reported Revenues for Q1FY24 of \u20b9195.00 Crores up from \u20b9165.00 Crore year on year, a rise of 18.18%. Total Expenses for Q1FY24 of \u20b9168.00 Crores up from \u20b9137.00 Crores year\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-787.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-787.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-787.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-787.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-787.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-787.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":162626,"url":"https:\/\/alphastreet.com\/india\/gufic-biosciences-ltd-q4fy24-11-rise-in-profits\/","url_meta":{"origin":156834,"position":1},"title":"Gufic BioSciences Ltd Q4FY24; 11% rise in Profits","author":"Divyansh_Kasana","date":"July 1, 2024","format":false,"excerpt":"Gufic Biosciences Limited is engaged in the manufacture of pharmaceuticals, medicinal chemicals and botanical products. Financial Results: Gufic BioSciences Ltd reported Revenues for Q4FY24 of \u20b9195.00 Crores up from \u20b9173.00 Crore year on year, a rise of 12.72%. Total Expenses for Q4FY24 of \u20b9169.00 Crores up from \u20b9150.00 Crores year\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/image-1.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/image-1.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/image-1.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/image-1.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/image-1.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/07\/image-1.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":164713,"url":"https:\/\/alphastreet.com\/india\/gufic-biosciences-ltd-q1fy25-4-rise-in-revenue\/","url_meta":{"origin":156834,"position":2},"title":"Gufic BioSciences Ltd Q1FY25; 4% rise in Revenue","author":"Divyansh_Kasana","date":"October 7, 2024","format":false,"excerpt":"Gufic Biosciences Limited is engaged in the manufacture of pharmaceuticals, medicinal chemicals and botanical products. Financial Results: Gufic BioSciences Ltd reported Revenues for Q1FY25 of \u20b9203.00 Crores up from \u20b9195.00 Crore year on year, a rise of 4.1%. Total Expenses for Q1FY25 of \u20b9176.00 Crores up from \u20b9168.00 Crores year\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/image-33.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/image-33.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/image-33.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/image-33.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/image-33.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/image-33.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":156403,"url":"https:\/\/alphastreet.com\/india\/gufic-biosciences-limited-q2-fy24-earnings-conference-call-insights\/","url_meta":{"origin":156834,"position":3},"title":"Gufic Biosciences Limited Q2 FY24 Earnings Conference Call Insights","author":"Praveen","date":"November 17, 2023","format":false,"excerpt":"Key highlights from Gufic Biosciences Limited (GUFICBIO) Q2 FY24 Earnings Concall New Product Launches and Approvals Launched new products like Dalbavancin and SeraSeal across divisions. The company received regulatory approvals for products in markets like Sri Lanka, Chile, Malaysia, Australia and Brazil. Expecting approvals for Immunocin-Alpha and dual-chamber bags with\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":154805,"url":"https:\/\/alphastreet.com\/india\/gufic-biosciences-advancements-strategic-developments-in-pharmaceuticals\/","url_meta":{"origin":156834,"position":4},"title":"Gufic BioSciences: Advancements &#038; Strategic Developments in Pharmaceuticals","author":"Hardik Bhandare","date":"October 11, 2023","format":false,"excerpt":"\u201cWe are also happy to announce that Gufic has secured DCGI approval for the manufacturing and marketing of Dalbavancin and we are the first Company to receive such approval in India. Trial for sepsis involving Immunocin Alpha have completed successfully and we anticipate the DGCI approval by Q3 of this\u2026","rel":"","context":"In &quot;Research Summary&quot;","block_context":{"text":"Research Summary","link":"https:\/\/alphastreet.com\/india\/category\/research-summary\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/b4654e61-a1d5-4b7f-8d9b-2f1140b01114-3.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/b4654e61-a1d5-4b7f-8d9b-2f1140b01114-3.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/b4654e61-a1d5-4b7f-8d9b-2f1140b01114-3.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/b4654e61-a1d5-4b7f-8d9b-2f1140b01114-3.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/b4654e61-a1d5-4b7f-8d9b-2f1140b01114-3.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/b4654e61-a1d5-4b7f-8d9b-2f1140b01114-3.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":128245,"url":"https:\/\/alphastreet.com\/india\/gufic-biosciences-limited-q3-fy22-earnings-conference-call-insights\/","url_meta":{"origin":156834,"position":5},"title":"Gufic Biosciences Limited Q3 FY22 Earnings Conference Call Insights","author":"Praveen","date":"March 14, 2022","format":false,"excerpt":"https:\/\/youtu.be\/f3tlyxhD91U Key highlights from Gufic Biosciences Limited (GUFICBIO) Q3 FY22 Earnings Concall Management Update: In CDMO, GUFICBIO said it\u2019s looking at a 9.4 million vials capacity per month which should make the company the largest manufacturer in the world. Q&A Highlights: Umang Shah from Sarath Capital AIF asked that the\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/156834","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1917"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=156834"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/156834\/revisions"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=156834"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=156834"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=156834"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}